Mark Lubberink1,2, Helena Wilking3, Amalia Öst3, Ezgi Ilan4,2, Mattias Sandström4,2, Camilla Andersson4, Katarzyna Fröss-Baron4,3, Irina Velikyan4,3, Anders Sundin4,3. 1. Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden mark.lubberink@radiol.uu.se. 2. Medical Physics, Uppsala University Hospital, Uppsala, Sweden; and. 3. Medical Imaging Centre, Uppsala University Hospital, Uppsala, Sweden. 4. Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Abstract
Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo in humans is crucial for personalized treatment management and understanding of treatment effects. Such an investigation requires input data on the in vivo stability of the radiopharmaceuticals in blood and plasma. The work presented here is devoted to the investigation of the in vivo stability of 177Lu-DOTATATE in humans affected by neuroendocrine tumors. Methods: Blood samples of 6 patients undergoing 177Lu-DOTATATE were taken at 0.5, 4, 24, and 96 h after injection. Analysis of metabolic stability was performed using high-performance liquid chromatography. Results: A fast metabolism of the radiopharmaceutical was observed, with the fraction of intact 177Lu-DOTATATE in plasma decreasing rapidly to 23% ± 5% (mean ± SD) at 24 h and 1.7% ±0. 9% at 96 h after injection. Conclusion: The in vivo stability of 177Lu-DOTATATE is much lower than previously assumed, with the major part of radioactivity in plasma consisting of 177Lu-labeled metabolites already at 24 h after injection.
Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo in humans is crucial for personalized treatment management and understanding of treatment effects. Such an investigation requires input data on the in vivo stability of the radiopharmaceuticals in blood and plasma. The work presented here is devoted to the investigation of the in vivo stability of 177Lu-DOTATATE in humans affected by neuroendocrine tumors. Methods: Blood samples of 6 patients undergoing 177Lu-DOTATATE were taken at 0.5, 4, 24, and 96 h after injection. Analysis of metabolic stability was performed using high-performance liquid chromatography. Results: A fast metabolism of the radiopharmaceutical was observed, with the fraction of intact 177Lu-DOTATATE in plasma decreasing rapidly to 23% ± 5% (mean ± SD) at 24 h and 1.7% ±0. 9% at 96 h after injection. Conclusion: The in vivo stability of 177Lu-DOTATATE is much lower than previously assumed, with the major part of radioactivity in plasma consisting of 177Lu-labeled metabolites already at 24 h after injection.
Authors: Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: Katarina Sjögreen Gleisner; Gustav Brolin; Anna Sundlöv; Edita Mjekiqi; Karl Östlund; Jan Tennvall; Erik Larsson Journal: J Nucl Med Date: 2015-05-21 Impact factor: 10.057
Authors: L A Bass; M V Lanahan; J R Duncan; J L Erion; A Srinivasan; M A Schmidt; C J Anderson Journal: Bioconjug Chem Date: 1998 Mar-Apr Impact factor: 4.774
Authors: Mattias Sandström; Ulrike Garske-Román; Dan Granberg; Silvia Johansson; Charles Widström; Barbro Eriksson; Anders Sundin; Hans Lundqvist; Mark Lubberink Journal: J Nucl Med Date: 2012-12-07 Impact factor: 10.057
Authors: Flavio Forrer; Eric P Krenning; Peter P Kooij; Bert F Bernard; Mark Konijnenberg; Willem H Bakker; Jaap J M Teunissen; Marion de Jong; Kirsten van Lom; Wouter W de Herder; Dik J Kwekkeboom Journal: Eur J Nucl Med Mol Imaging Date: 2009-02-27 Impact factor: 9.236
Authors: Linn Hagmarker; Johanna Svensson; Tobias Rydén; Martijn van Essen; Anna Sundlöv; Katarina Sjögreen Gleisner; Peter Gjertsson; Peter Bernhardt Journal: J Nucl Med Date: 2019-03-22 Impact factor: 10.057
Authors: Hendrik Bergsma; Mark W Konijnenberg; Boen L R Kam; Jaap J M Teunissen; Peter P Kooij; Wouter W de Herder; Gaston J H Franssen; Casper H J van Eijck; Eric P Krenning; Dik J Kwekkeboom Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-30 Impact factor: 9.236